Your session is about to expire
← Back to Search
Cabozantinib for Melanoma
Study Summary
This trial is testing a combination of three drugs to treat melanoma. The drugs will be given for 12 weeks, followed by maintenance therapy for up to 2 years. The goal is to see how well the combination works in preventing disease progression.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available positions for patients in this trial?
"Yes, this experiment is still ongoing and looking for volunteers. The trial was announced on March 2nd, 2020 and has had two updates since then; the most recent being on May 3rd, 2022."
How many people have been asked to participate in this clinical trial?
"Yes, this clinical trial is still recruiting patients. Per the information available on clinicaltrials.gov, the original posting was on March 2nd, 2020. The most recent update was on May 3rd, 2022. They are currently looking for 27 individuals to participate at 3 different locations."
What are the short-term and long-term effects of Cabozantinib?
"Because this is a Phase 2 trial, there is clinical evidence indicating that Cabozantinib is safe for human use. However, its efficacy has not yet been studied."
What medical conditions does Cabozantinib help to treat?
"Cabozantinib is most often used to treat melanoma that cannot be surgically removed. However, it can also help patients with squamous cell carcinoma and a high risk of disease recurrence."
Are there other ongoing or completed research projects that have looked at Cabozantinib?
"The first clinical trial studying the effects of cabozantinib was completed in 2009 at Texas Children's Hospital. Since then, there have been a total of 415 clinical trials evaluating this medication. As of now, 879 different clinical trials are ongoing with numerous sites based in Hackensack, New jersey."
Share this study with friends
Copy Link
Messenger